Treatment of HRD+ Advanced Ovarian Cancer After Three or More Chemotherapies

QUADRA

  • Study Design

    QUADRA evaluated ZEJULA as treatment in 4th-line+ patients, including those with BRCA– or platinum-resistant disease1

    QUADRA was a single-arm, phase 2 trial of patients with advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy (N=463), including HRD+ patients.1,2

    QUADRA trial data
    QUADRA trial data
    shadow-divider

    Patient Characteristics in the QUADRA Trial (N=463) Were Representative of a Real-World, Late-Line Population2:

    • 27% of patients were 6th line or later
    • 68% of patients were platinum resistant or refractory

    The FDA Indication Is for HRD+ Patients (in QUADRA, n=98) With Either1:

    • BRCA+ tumors regardless of platinum status
    • BRCA- tumors with genomic instability (GIS+) and had progressed more than 6 months after the last platinum-based chemotherapy 
    64% BRCA+ and 36% BRCA-, GIS+ platinum-sensitive
    64% BRCA+ and 36% BRCA-, GIS+ platinum-sensitive

    *19% of patients were 6th line or later.

    BRCA+, breast cancer susceptibility gene mutated; BRCA-, not BRCA-mutated; GIS, genomic instability score; HRD+, homologous recombination deficiency positive; ORR, overall response rate. 

  • 4th-Line+ Efficacy

    Indicated for the Treatment of 4th-Line+ Homologous Recombination Deficiency Positive (HRD+) Ovarian Cancer Defined by Either1:

    QUADRA indication
    QUADRA indication
    shadow-divider

    Clinically Meaningful, Durable Benefit Was Observed1

    Median duration of response in the indicated population

    Graph showing the median duration of response in the indicated population.

    BRCA+, breast cancer susceptibility gene mutated; BRCA-, not BRCA-mutated; CI, confidence interval; GIS, genomic instability score; HRD+, homologous recombination deficiency positive; ORR, overall response rate.

SAFETY DATA

Learn about the safety
and tolerability of ZEJULA

Dose
Modifications

See recommendations for dose adjustments